Global Edition
Global Edition
UK Edition
EU Edition
US Edition

Understand the story, not the spin.

Markets

AriBio reports AR1001 benefit in Alzheimer’s subgroup

Published 18 November 2026 · All stories from this day

AriBio said its experimental Alzheimer’s drug AR1001 slowed clinical decline by 31% over 52 weeks in a prespecified group of 604 people with early Alzheimer’s who were not taking other Alzheimer’s medicines. The company reported no statistically significant benefit across the full 1,535-person trial population, tempering the result’s relevance to patients using those medicines.

The phase 3 POLARIS-AD trial measured decline using the Clinical Dementia Rating Sum of Boxes, an 18-point scale assessing areas including memory, judgment and daily activities. In the group taking AR1001 without other Alzheimer’s drugs, scores worsened 0.44 points less than with placebo, a difference AriBio said was statistically significant. The company described that as 31% slowing.

Across all 1,535 participants, the reported difference was 0.11 points, or about 7% slowing, and was not statistically significant. The trial included 931 people who were already taking common Alzheimer’s medicines for most of the study. The company’s topline results therefore showed a positive finding in the prespecified group, but not across the overall trial.

AriBio presented the findings at the Clinical Trials on...

Now playing
0:00 / 0:00